The investigators propose a single-center, non-randomized, single-arm study at the Barrow
Neurological Institute/St. Joseph's Hospital for recurrent glioma. The 5-ALA for recurrent
glioma study will correlate presence of fluorescence in tumor tissue with pathological
findings. This will be done using three cohorts in dose escalation. The investigators'
hypothesis is that (for both low- and high-grade gliomas,) a lower dose of 5-ALA will result
in less false positive fluorescence.